Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 19Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Primary Myelofibrosis 1

Interventions

nilotinib 5venetoclax 3midostaurin 3ponatinib 2navitoclax 2gilteritinib 2fludarabine phosphate 2asparaginase erwinia chrysanthemi recombinant 2tisagenlecleucel 1revumenib 1pirtobrutinib 1magrolimab 1ivosidenib 1immunotoxin HA22 1idelalisib 1ibrutinib 1glucarpidase 1fludarabine 1eryaspase 1enasidenib 1cc-486 1brexucabtagene autoleucel 1asciminib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × navitoclax × Other hematologic neoplasm × Clear all
NCT05215405 2025-02-03

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

University of Texas Southwestern Medical Center

No longer available
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03592576 2024-05-06

Expanded Access to Navitoclax

AbbVie

No longer available
LymphoidMyeloidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡